https://www.selleckchem.com/pr....oducts/epz015666.htm
of bias were identified. The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94-9027 (damoctocog alfa pegol; Jivi ), a B-domain-deleted recombinant factor VIII (FVIII), site-specifically PEGylated to extend its half-life. To report the final efficacy and safety data for BAY 94-9027 from the PROTECT VIII extension. Previously treated males aged 12-65years with severe haemophilia A (FVIII 1%) who completed the multicentre, open-label PROTECT VIII main study were eligible for the extension. Patients received
Like
Comment
Share
